Hologic (HOLX) : Traders are bullish on Hologic (HOLX) as it has outperformed the S&P 500 by a wide margin of 5.83% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.82%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.25% in the last 1 week, and is up 8.46% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Hologic (NASDAQ:HOLX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $38.93 and $38.77 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $38.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $38.97, notching a gain of 0.75% for the day. The total traded volume was 1,498,280 . The stock had closed at $38.68 on the previous day.
The stock has recorded a 20-day Moving Average of 5.08% and the 50-Day Moving Average is 10.24%. Hologic Inc. is up 15.57% in the last 3-month period. Year-to-Date the stock performance stands at 0.72%.
Hologic (HOLX) stock is expected to deviate a maximum of $2.5 from the average target price of $42.08 for the short term period. 13 Street Experts have initiated coverage on the stock with the most promising target being $46 and the most muted being $39.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.